Exemplos de uso de Time to treatment em Inglês e suas traduções para o Português
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
Time to treatment failure.
For the main analyses,we categorized time to treatment using a cutoff at 3 hours.
Time to treatment failure months.
In all models,the dependent variable was the time to treatment, categorized using a cutoff at 3 hours.
Time to treatment failure months.
Benefits in clinical outcomes with thrombectomy cannot be explained by a shorter time to treatment.
Time to treatment failure(months) 95% CI.
Figure 1: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after Week 6(Study UV I) or Week 2 Study UV II.
Time to treatment failure(months) 95% CI.
We present the bivariate analysis for the association between the unit of first contact and time to treatment using a cutoff at 3 hours.
Time to Treatment Failure in Studies UV I and UV II.
We built crude and adjusted for age, sex, ACS subtype andeducational level binary logistic regression models to study if the unit of first contact influenced time to treatment.
Time to Treatment Failure At or After Week 2 in Study UV II.
After adjustment for age, sex, ACS subtype and educational level,we found that initial presentation at primary care units was directly associated with time to treatment with aspirin shorter than 3 hours p.
Time to treatment was analyzed for NSTEACS and STEMI participants in separate.
Secondary endpoints included progression-free survival(PFS), objective response rate(ORR),clinical benefit rate, time to treatment failure(TTF), and quality adjusted survival measurement.
The time to treatment was near to the ideal, which is considered to be around 2 hours.
In thrombolytic studies,patients in the United States US tended to have shorter time to treatment, lower Killip class and a higher proportion of inferior myocardial infarctions MIs than non-US patients.
Time to treatment was defined as the time between patient arrival at the unit of first contact and medication administration.
The advance of current bioengineering has been driven by the increasing need of humanity to seek ways to alleviate the suffering,ensure time to treatment, improve the quality of life or cure medical conditions of patients.
In this scenario, time to treatment may be a useful marker of the quality of care during an ACS event.
For the subsample of individuals with STEMI who received thrombolytic therapy,we did not find a significant association between the unit of first contact and time to treatment with thrombolytic therapy shorter than 3 hours in adjusted models p=0.12.
Mean exposure time to treatment was 2.09± 2.39 years, with 750 patients using biologic agents and 287 using only DMARDs.
The beneficial effect of enoxaparin on the primary endpoint was consistent across key subgroups including age, gender, infarct location, history of diabetes, history of prior myocardial infarction,fibrinolytic administered and time to treatment with study medicinal product.
Kaplan-Meier analysis showed shorter time to treatment failure in patients treated with gliclazide, compared with pioglitazone.
In addition, time to treatment initiation after symptom onset was found to be higher in the patients who required hospitalization.
A clinical trial of pioglitazone vs. gliclazide as monotherapy was extended to two years in order to assess time to treatment failure defined as appearance of HbA1c≥ 8.0% after the first six months of therapy.
Time to treatment in patients with and without an outcome in the STEMI subgroup was compared with Student's t test or Mann-Whitney test, depending on their distributions.
Combined 48-week median time to treatment failure for both studies was 115 days in the APTIVUS/ ritonavir arm and 0 days in the comparator arm no treatment response was imputed to day 0.
Median time to treatment failure in responders was 122 weeks(95% C.I 106-147), while in the overall study population it was 84 weeks 95% C.I 71-109.